Physician profile
Deon Middlebrook
NPI 1508898123
$840.56
in general payments reported to CMS, 2019-2025
13 companies · $69.87 in 2025
The $69.87 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $33.65 · 2021: $15.90 · 2022: $120 · 2023: $21.43 · 2024: $124 · 2025: $69.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $195 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.18 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $172.70 | 2019 | |
| Medline Industries Lp | $117.68 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $89.26 | 2019-2025 | Farxiga |
| Amgen INC. | $86.20 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $85.98 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.94 | 2022-2024 | |
| Akebia Therapeutics INC | $46.81 | 2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $38.85 | 2022 | |
| Fresenius USA Marketing, INC. | $36.78 | 2019-2024 | Crit-Line |
| Otsuka America Pharmaceutical, INC. | $33.19 | 2019-2020 | |
| Ardelyx, INC. | $25.93 | 2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $20.23 | 2020 | |
| Novo Nordisk INC | $17.01 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deon Middlebrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.